AU2009326204B2 - Anti-viral protection with viruses containing defective genome segments - Google Patents

Anti-viral protection with viruses containing defective genome segments Download PDF

Info

Publication number
AU2009326204B2
AU2009326204B2 AU2009326204A AU2009326204A AU2009326204B2 AU 2009326204 B2 AU2009326204 B2 AU 2009326204B2 AU 2009326204 A AU2009326204 A AU 2009326204A AU 2009326204 A AU2009326204 A AU 2009326204A AU 2009326204 B2 AU2009326204 B2 AU 2009326204B2
Authority
AU
Australia
Prior art keywords
virus
influenza
mice
infection
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009326204A
Other languages
English (en)
Other versions
AU2009326204A1 (en
Inventor
Nigel Dimmock
Andrew Easton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Warwick
Original Assignee
University of Warwick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Warwick filed Critical University of Warwick
Publication of AU2009326204A1 publication Critical patent/AU2009326204A1/en
Application granted granted Critical
Publication of AU2009326204B2 publication Critical patent/AU2009326204B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2009326204A 2008-12-12 2009-12-08 Anti-viral protection with viruses containing defective genome segments Ceased AU2009326204B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0822672.2A GB0822672D0 (en) 2008-12-12 2008-12-12 Anti-viral protection with viruses containing a defective genome
GB0822672.2 2008-12-12
PCT/GB2009/051666 WO2010067109A1 (en) 2008-12-12 2009-12-08 Anti-viral protection with viruses containing defective genome segments

Publications (2)

Publication Number Publication Date
AU2009326204A1 AU2009326204A1 (en) 2011-06-23
AU2009326204B2 true AU2009326204B2 (en) 2014-01-09

Family

ID=40325992

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009326204A Ceased AU2009326204B2 (en) 2008-12-12 2009-12-08 Anti-viral protection with viruses containing defective genome segments

Country Status (11)

Country Link
US (1) US8691215B2 (enExample)
EP (1) EP2355834B1 (enExample)
CN (1) CN102256611B (enExample)
AU (1) AU2009326204B2 (enExample)
CA (1) CA2746495C (enExample)
DK (1) DK2355834T3 (enExample)
ES (1) ES2423193T3 (enExample)
GB (1) GB0822672D0 (enExample)
IN (1) IN2011KN02819A (enExample)
PL (1) PL2355834T3 (enExample)
WO (1) WO2010067109A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2019685T3 (pl) * 2006-05-24 2015-04-30 Univ Warwick Defektywny interferujący wirus
GB2522615A (en) * 2014-01-16 2015-08-05 Univ Warwick Assay and medicament
WO2019206285A1 (en) * 2018-04-26 2019-10-31 The University Of Hong Kong Nucleic acid molecules and dual-functional peptides having antiviral activity and delivery activity, compositions and methods thereof
GB202209861D0 (en) * 2022-07-05 2022-08-17 Univ Court Univ St Andrews Viral vectors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007135420A2 (en) * 2006-05-24 2007-11-29 The University Of Warwick Defective interfering virus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
EP1796719B1 (en) 2004-10-06 2014-12-03 MedImmune, LLC Refrigerator-temperature stable influenza vaccine compositions
KR20070100882A (ko) 2004-11-11 2007-10-12 솔베이 파마슈티칼스 비. 브이 결손 인플루엔자 바이러스 입자
GB2437799B (en) * 2006-05-24 2008-08-13 Univ Warwick Defective interfering virus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007135420A2 (en) * 2006-05-24 2007-11-29 The University Of Warwick Defective interfering virus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DUHAUT S. D. ET AL, VIROLOGY, vol. 248, no. 2, pages 241-253, 1998 *

Also Published As

Publication number Publication date
GB0822672D0 (en) 2009-01-21
EP2355834B1 (en) 2013-05-01
EP2355834A1 (en) 2011-08-17
US8691215B2 (en) 2014-04-08
US20110243896A1 (en) 2011-10-06
IN2011KN02819A (enExample) 2015-07-10
CA2746495C (en) 2018-04-17
CN102256611B (zh) 2014-05-21
WO2010067109A1 (en) 2010-06-17
CN102256611A (zh) 2011-11-23
PL2355834T3 (pl) 2014-03-31
DK2355834T3 (da) 2013-07-29
ES2423193T3 (es) 2013-09-18
AU2009326204A1 (en) 2011-06-23
CA2746495A1 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
Easton et al. A novel broad-spectrum treatment for respiratory virus infections: influenza-based defective interfering virus provides protection against pneumovirus infection in vivo
Dimmock et al. Defective interfering influenza virus RNAs: time to reevaluate their clinical potential as broad-spectrum antivirals?
US10793834B2 (en) Live-attenuated virus and methods of production and use
Whittaker Intracellular trafficking of influenza virus: clinical implications for molecular medicine
US9827304B2 (en) Live attenuated vaccines for influenza viruses
Mann et al. Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to reinfection
US9089516B2 (en) Method of preventing or treating influenza A viral infection using cloned DI influenza A viral particles
CA2746495C (en) Anti-viral protection with viruses containing a defective genome
Scott et al. Defective interfering virus protects elderly mice from influenza
Pu et al. Synergism of co-mutation of two amino acid residues in NS1 protein increases the pathogenicity of influenza virus in mice
CN101454023B (zh) 干扰缺损病毒
US10272149B2 (en) Modified bat influenza viruses and their uses
WO2020163768A1 (en) Stabilized 9 and 10 segmented influenza viruses as a vaccine platform and methods of making and using same
KR101582490B1 (ko) 인플루엔자 바이러스의 다중 아형에 대한 교차 면역반응을 형성하는 신규한 재조합 바이러스 백신
EP3939991A2 (en) Novel recombinant influenza virus having immune and therapeutic responses to heterologous influenza virus, and genetic vector and therapeutic vaccine comprising same
Ngunjiri Influenza virus noninfectious biologically active particle subpopulations: Detection, quantification, genetic complexity, function and their novel use as an in vitro screen for self-adjuvating live-attenuated influenza vaccines
Hoffmann The identification of novel antivirals and enhancers of influenza virus replication via high-throughput screening of small molecular weight compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)